Cardio Diagnostics shares jump 21.15% premarket after partnering with Aimil and Dr. Lal PathLabs to launch PrecisionCHD in India.

Cardio Diagnostics Holdings, Inc. (CDIO) surged 21.15% in premarket trading following the announcement of two major partnerships. The company partnered with Southdale YMCA to expand heart health education and advanced cardiovascular testing in the Edina, Minnesota community, enhancing local access to its AI-powered diagnostics. Simultaneously, CDIO announced its first international expansion into India via a strategic agreement with Aimil Ltd. and Dr. Lal PathLabs, marking entry into a critical market with high cardiovascular disease prevalence. The India partnership, involving the launch of its PrecisionCHD™ test through a leading diagnostics network, underscores the company’s global growth strategy and validates its technology’s potential to address significant unmet medical needs. These developments, particularly the international expansion, likely drove the sharp premarket rally, reflecting investor optimism about expanded market reach and revenue opportunities.